Skip to main content
. 2022 Aug 26;23:714. doi: 10.1186/s13063-022-06649-3

Fig. 2.

Fig. 2

Kaplan–Meier survival analysis curve for time to resolution of symptoms in the ivermectin group (n=32) versus controls (n=32) (p=0.553)